Min Yao, PhD, is a Senior Drug Development Manager in the MSK Therapeutics Bridge Labs (TxBL) program in the Office of Entrepreneurship & Commercialization. He oversees therapeutic antibody discovery for the TxBL team and joined MSK in September 2025.
Previously, Min was Associate Director in the Sanders Tri-Institute Therapeutics Discovery Institute, focusing on therapeutic antibody discovery. He previously obtained postdoctoral training in Cold Spring Harbor Laboratory, focusing on B cell biology and cancer antigen.
Min received his bachelor’s degree in biotechnology from Shanghai Jiao Tong University (China) in 2008, a master’s degree in cell biology from University of Kansas Medical Center and Stowers Institute for Medical Research in 2013, and a PhD in cancer biology from University of Kansas Medical Center in 2017.